Appropriate doses of non-vitamin K antagonist oral anticoagulants in high-risk subgroups with atrial fibrillation: Systematic review and meta-analysis

Kirchhof, 2016, 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS, Eur Heart J, 37, 2893, 10.1093/eurheartj/ehw210 Hylek, 2008, Disparate stroke rates on warfarin among contemporaneous cohorts with atrial fibrillation: potential insights into risk from a comparative analysis of SPORTIF III versus SPORTIF V, Stroke, 39, 3009, 10.1161/STROKEAHA.108.514935 2007, Independent predictors of stroke in patients with atrial fibrillation: a systematic review, Neurology, 69, 546, 10.1212/01.wnl.0000267275.68538.8d Pisters, 2010, A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey, Chest, 138, 1093, 10.1378/chest.10-0134 Garcia, 2010, New-onset atrial fibrillation and warfarin initiation: high risk periods and implications for new antithrombotic drugs, Thromb Haemost, 104, 1099, 10.1160/TH10-07-0491 Lip, 2010, Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro heart survey on atrial fibrillation, Chest, 137, 263, 10.1378/chest.09-1584 Ezekowitz, 2010, Dabigatran and warfarin in vitamin K antagonist-naive and -experienced cohorts with atrial fibrillation, Circulation, 122, 2246, 10.1161/CIRCULATIONAHA.110.973735 Mahaffey, 2013, Clinical outcomes with rivaroxaban in patients transitioned from vitamin K antagonist therapy: a subgroup analysis of a randomized trial, Ann Intern Med, 158, 861, 10.7326/0003-4819-158-12-201306180-00003 Garcia, 2013, Apixaban versus warfarin in patients with atrial fibrillation according to prior warfarin use: results from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation trial, Am Heart J, 166, 549, 10.1016/j.ahj.2013.05.016 O’Donoghue, 2015, Edoxaban vs. warfarin in vitamin K antagonist experienced and naive patients with atrial fibrillation, Eur Heart J, 36, 1470, 10.1093/eurheartj/ehv014 Diener, 2010, Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial, Lancet Neurol, 9, 1157, 10.1016/S1474-4422(10)70274-X Hankey, 2012, Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF, Lancet Neurol, 11, 315, 10.1016/S1474-4422(12)70042-X Easton, 2012, Apixaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of the ARISTOTLE trial, Lancet Neurol, 11, 503, 10.1016/S1474-4422(12)70092-3 Rost, 2016, Outcomes with edoxaban versus warfarin in patients with previous cerebrovascular events: findings from ENGAGE AF-TIMI 48 (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48), Stroke, 47, 2075, 10.1161/STROKEAHA.116.013540 Ntaios, 2017, Nonvitamin-K-antagonist oral anticoagulants versus warfarin in patients with atrial fibrillation and previous stroke or transient ischemic attack: an updated systematic review and meta-analysis of randomized controlled trials, Int J Stroke, 12, 589, 10.1177/1747493017700663 Ntaios, 2012, Nonvitamin-K-antagonist oral anticoagulants in patients with atrial fibrillation and previous stroke or transient ischemic attack: a systematic review and meta-analysis of randomized controlled trials, Stroke, 43, 3298, 10.1161/STROKEAHA.112.673558 Ruff, 2014, Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials, Lancet, 383, 955, 10.1016/S0140-6736(13)62343-0 2011 Tanahashi, 2013, Rivaroxaban versus warfarin in Japanese patients with nonvalvular atrial fibrillation for the secondary prevention of stroke: a subgroup analysis of J-ROCKET AF, J Stroke Cerebrovasc Dis, 22, 1317, 10.1016/j.jstrokecerebrovasdis.2012.12.010 Kim, 2013, Testing a tool for assessing the risk of bias for nonrandomized studies showed moderate reliability and promising validity, J Clin Epidemiol, 66, 408, 10.1016/j.jclinepi.2012.09.016 Schunemann, 2013 Eisen, 2016, Am Heart J, 172, 144, 10.1016/j.ahj.2015.11.004 Connolly, 2008, Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range, Circulation, 118, 2029, 10.1161/CIRCULATIONAHA.107.750000 Connolly, 2009, Dabigatran versus warfarin in patients with atrial fibrillation, N Engl J Med, 361, 1139, 10.1056/NEJMoa0905561 Patel, 2011, Rivaroxaban versus warfarin in nonvalvular atrial fibrillation, N Engl J Med, 365, 883, 10.1056/NEJMoa1009638 Granger, 2011, Apixaban versus warfarin in patients with atrial fibrillation, N Engl J Med, 365, 981, 10.1056/NEJMoa1107039 Giugliano, 2013, Edoxaban versus warfarin in patients with atrial fibrillation, N Engl J Med, 369, 2093, 10.1056/NEJMoa1310907 Hori, 2012, Rivaroxaban vs. warfarin in Japanese patients with atrial fibrillation – the J-ROCKET AF study, Circ J, 76, 2104, 10.1253/circj.CJ-12-0454 Gage, 2001, Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation, JAMA, 285, 2864, 10.1001/jama.285.22.2864 Wolf, 1991, Atrial fibrillation as an independent risk factor for stroke: the Framingham Study, Stroke, 22, 983, 10.1161/01.STR.22.8.983 1993, Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. EAFT (European Atrial Fibrillation Trial) Study Group, Lancet, 342, 1255, 10.1016/0140-6736(93)92358-Z Saxena, 2004, Anticoagulants versus antiplatelet therapy for preventing stroke in patients with nonrheumatic atrial fibrillation and a history of stroke or transient ischemic attack, Cochrane Database Syst Rev Lasek-Bal, 2016, Rivaroxaban in secondary cardiogenic stroke prevention: two-year single-centre experience based on follow-up of 209 patients, Kardiol Pol, 74, 418, 10.5603/KP.a2015.0207 Xian, 2015, Real world effectiveness of warfarin among ischemic stroke patients with atrial fibrillation: observational analysis from Patient-Centered Research into Outcomes Stroke Patients Prefer and Effectiveness Research (PROSPER) study, BMJ, 351, h3786, 10.1136/bmj.h3786 Ezekowitz, 1992, Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators, N Engl J Med, 327, 1406, 10.1056/NEJM199211123272002 Yao, 2017, antagonist oral anticoagulant dosing in patients with atrial fibrillation and renal dysfunction, J Am Coll Cardiol, 69, 2779, 10.1016/j.jacc.2017.03.600 Nielsen, 2017, Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study, BMJ, 356, j510, 10.1136/bmj.j510 Jackevicius, 2017, Early non-persistence with dabigatran and rivaroxaban in patients with atrial fibrillation, Heart, 103, 1331, 10.1136/heartjnl-2016-310672 King, 2005, Impact of participant and physician intervention preferences on randomized trials: a systematic review, JAMA, 293, 1089, 10.1001/jama.293.9.1089 Schulman, 2005, Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients, J Thromb Haemost, 3, 692, 10.1111/j.1538-7836.2005.01204.x Boudes, 2006, The challenges of new drugs benefits and risks analysis: lessons from the ximelagatran FDA Cardiovascular Advisory Committee, Contemp Clin Trials, 27, 432, 10.1016/j.cct.2006.04.005